Skip to main content Accessibility help


  • William K. Evans (a1), Michael C. Wolfson (a2), William M. Flanagan (a3), Janey Shin (a4), John Goffin (a5), Anthony B. Miller (a6), Keiko Asakawa (a7), Craig Earle (a8), Nicole Mittmann (a9), Lee Fairclough (a4), Jillian Oderkirk (a3), Philippe Finès (a3), Stephen Gribble (a3), Jeffrey Hoch (a10), Chantal Hicks (a3), D. Walter R. Omariba (a3) and Edward Ng (a3)...


Objectives: The aim of this study was to develop a decision support tool to assess the potential benefits and costs of new healthcare interventions.

Methods: The Canadian Partnership Against Cancer (CPAC) commissioned the development of a Cancer Risk Management Model (CRMM)—a computer microsimulation model that simulates individual lives one at a time, from birth to death, taking account of Canadian demographic and labor force characteristics, risk factor exposures, and health histories. Information from all the simulated lives is combined to produce aggregate measures of health outcomes for the population or for particular subpopulations.

Results: The CRMM can project the population health and economic impacts of cancer control programs in Canada and the impacts of major risk factors, cancer prevention, and screening programs and new cancer treatments on population health and costs to the healthcare system. It estimates both the direct costs of medical care, as well as lost earnings and impacts on tax revenues. The lung and colorectal modules are available through the CPAC Web site ( to registered users where structured scenarios can be explored for their projected impacts. Advanced users will be able to specify new scenarios or change existing modules by varying input parameters or by accessing open source code. Model development is now being extended to cervical and breast cancers.



Hide All
1.Canadian Partnership against Cancer. (accessed December 15, 2012).
2.Wolfson, WC.POHEM—a framework for understanding and modeling the health of human populations. World Health Stat Q. 1994;47:157176.
3.American Cancer Society Cancer Statistics 2009 Presentation. (accessed August 20, 2011).
4.Canadian Cancer Society's Steering Committee. Canadian cancer statistics 2009. Toronto: Canadian Cancer Society, 2009.
5.Moller, H, Fairley, L, Coupland, V, et al.The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer. 2007;96:14841488.
6.Smoke-free Ontario Cessation and Prevention Programs. (accessed September 17, 2011).
7.National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395409.
8.Winton, T, Livingston, R, Johnson, D, et al.Vinorelbine plus cisplatin versus observation in resected non-small cell lung cancer. N Engl J Med. 2005;352:25892597.
9.Goffin, J, Coakley, N, Ellis, P, et al. Cancer Care Ontario Evidence-based series #7–10. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: Evidentiary base 2009. (accessed December 20, 2011).
10.ColonCancerCheck. (accessed December 20, 2011).
11.Jonker, D, Spithoff, K, Maroun, J.Adjuvant systemic chemotherapy for stage II and III colon cancer following complete resection: Guidelines recommendations. Evidence-based series #2–29 (accessed Month day, year).
12.Segal, NH, Saltz, LB.Evolving treatment of advanced colon cancer. Annu Rev Med. 2009;60:207219.
13.Evans, WK, Will, BP, Berthelot, J-M, Wolfson, MC.Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Can J Oncol. 1995;5:408419.
14.Maroun, J, Ng, E, Berthelot, J-M, et al.Lifetime costs of colon and rectal cancer management in Canada. Chronic Dis Can. 2003;24:91101.
15.Will, BP, Berthelot, J-M, LePetit, C, et al.Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer. 2000;36:724735.
16.Will, BP, Le Petit, C, Berthelot, J-M, et al.Diagnostic and therapeutic approaches for non-metastatic breast cancer in Canada, and their associated costs. Br J Cancer. 1999;79:14281436.
17.Berthelot, J-M, Will, BP, Evans, WK, et al.Decision framework for chemotherapeutic interventions for metastatic non-small cell lung cancer. J Natl Cancer Inst. 2000;92:13211329.
18.Evans, WK, Will, BP, Berthelot, J-M, et al.Breast cancer: Better care for less cost: Is it possible? Int J Technol Assess Health Care. 2000;16:11681178.
19.Flanagan, W, Le Petit, C, Berthelot, J-M, et al.Potential impact of population-based colorectal cancer screening in Canada. Chronic Dis Can. 2003;24:8188.
20.Will, BP, Berthelot, J-M, Nobrega, KM, Flanagan, W, Evans, WK.Canada's Population Health Model (POHEM): A tool for performing economic evaluations of cancer control interventions. Eur J Cancer. 2001;37:17971804.
21.Will, BP, Nobrega, KM, Berthelot, J-M, et al.First do no harm: Extending the debate on the provision of preventive tamoxifen. Br J Cancer. 2001;85:12801288.
22.Whittemore, AS, McMillan, A.Lung cancer mortality among US uranium miners: A reappraisal. J Natl Cancer Inst. 1983;71:489499.
23.Winawer, SJ, Zauber, AG, Ho, MN, et al.Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med. 1993;329:19771981.
24.Kronborg, O, Fenger, C, Olsen, J, Jorgensen, OD, Sondergaard, O.Randomized study of screening for colorectal cancer with fecal occult blood test. Lancet. 1996;348:14671471.
25.Church, TR, Mandel, JS, Bond, JH, Ederer, F.Colorectal cancer incidence reduction due to polyp removal: Results from the Minnesota trial. Gastroenterology. 2003;124 (Suppl 1):A55.
26.Lieberman, DA.Screening for colorectal cancer. N Engl J Med. 2009;361:11791187.
27.Horsman, J, Furlong, W, Feeney, D, Torrance, G.The Health Utilities Index (HUI): Concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54.
28.Statistics Canada. National population health survey. (accessed December 20, 2011).
29.Statistics Canada. Canadian community health survey. (accessed November 26, 2011).
30.Evans WK, Connor Gorber SK, Spence ST, Will BP; for the Population Health Impact of Disease in Canada (PHI). Health state descriptions for Canadians. Cancers. Statistics Canada, catalogue no. 82–619-MIE2005001. Ottawa: Statistics Canada, 2005
31.McIntosh, CN, Gorber, S, Bernier, J, Berthelot, J-M. Eliciting Canadian population preferences for health states using the Classification and Measurement System of Functional Health (CLAMES). Chron Dis Can. 2007;28:2941.
32.Flanagan, WM, McIntosh, CN, Berthelot, J-M, LePetit, C.Deriving utility scores for co-morbid conditions: a test of the multiplicative model for combining individual condition scores. Popul Health Metr. 2006;4:13 doi:10.1186/1478–7954-4-13.
33.Statistics Canada. General social survey. (accessed November 26, 2011).
34.Statistics Canada. Canada health survey. (accessed November 26, 2011).
35.Navaratnam, S, Kliever, EV, Butler, J, et al.Population-based patterns and cost management of metastatic non-small cell lung cancer after completion of chemotherapy until death. Lung Cancer. 2010;70:110115. doi:10.1016/j.lungcan.2010.01.012.
36.Statistics Canada. 2007. 2006 census dictionary. Statistics Canada catalogue no. 92 – 566 – XWE. Ottawa. (accessed November 26, 2011)
37.Bordt, M, Cameron, G, Gribble, S, et al.The social policy simulation database and model: An integrated tool for tax/transfer policy analysis. Can Tax J. 1990;38. Cancer risk management model 1.0. (accessed January 7, 2012).
39.Butts, CA, Ding, K, Seymour, L, et al.Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: Updated survival analysis of JBR-10. J Clin Oncol. 2009;28:2934.
40.Evans, WK, Feld, R, Murray, N, et al.Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. Ann Int Med. 1987;107:451458.
41.Feld, R, Evans, WK, Coy, P, et al.Canadian multicentre randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol. 1987;5:14011409.
42.Holmes EC, Gail M, for the Lung Cancer Study Group. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol. 1986;4:710715.
43.Johnson, DH, Einhorn, LH, Bartolucci, A, et al.Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Int Med. 1990;113:3338.
44.Mountain, CM, Gail, MH.The Lung Cancer Study Group: Surgical adjuvant intrapleural BCG treatment for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 1981;82:649657.
45.Perez, CA, Stanley, K, Rubin, P, et al.A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung: Preliminary Report by the Radiation Therapy Oncology Group. Cancer. 1980;45:27442753.
46.Rapp, E, Pater, JL, Willan, A, et al.Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer. Report of a Canadian multicentre randomized trial. J Clin Oncol. 1988;6:633641.
47.McGregor, R, Vasudev, P, Letourneau, E, et al.Background concentration of radon and radon daughters in Canadian homes. Health Phys. 1980;39:285289.
48.Eheman, C, Henley, SJ, Ballard-Barbash, R, et al.Annual report to the nation on the status of cancer 1975–2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118:23382366. doi:10.1002/cncr.27514
49.Fojo, T, Grady, C.How much is life worth: cetuximab, non-small cell lung cancer and the $440 billion question. J Natl Cancer Inst. 2009;101:10441048.
50.Breakaway: The global burden of cancer – challenges and opportunities. A report from the Economist Intelligence Unit. (accessed Month day, year).


Type Description Title
Supplementary materials

Evans et al. supplementary material
Supplementary tables

 Word (52 KB)
52 KB


  • William K. Evans (a1), Michael C. Wolfson (a2), William M. Flanagan (a3), Janey Shin (a4), John Goffin (a5), Anthony B. Miller (a6), Keiko Asakawa (a7), Craig Earle (a8), Nicole Mittmann (a9), Lee Fairclough (a4), Jillian Oderkirk (a3), Philippe Finès (a3), Stephen Gribble (a3), Jeffrey Hoch (a10), Chantal Hicks (a3), D. Walter R. Omariba (a3) and Edward Ng (a3)...


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed